Video Information:
The first CAR T-cell therapy to receive FDA approval, CTL019 (Kymriah) was recently approved for children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Expert Dr. Michael Deinginger joins Patient Power Founder Andrew Schorr to explain CAR T-cell therapy, an approach that uses the body’s own system to fight the disease. Find out why Dr. Deininger calls this approval “revolutionary.”
Published By :
Patient Power
Date :
Oct 25, 2017
